Business Development Provide advice and assistance in business growth and development of Party B. 业务发展。对乙方的业务发展提供建议和协助。
Regulatory Affairs From the point in time at which Novartis gives GW notice in writing that it wishes to take on responsibility for Regulatory Filings and Regulatory Approvals in the Territory, Novartis shall be responsible for all interactions with Regulatory Authorities in the Territory with respect to Regulatory Approvals as set forth in this Section 6.1, and including, filing and maintaining any required Regulatory Approvals, seeking necessary permits and/or scheduling or re-scheduling in controlled substance listings or de-scheduling of the Product from controlled substances listings in the Territory.
(a) Where required, Novartis (or its applicable Affiliate or Sublicensee) will be responsible for arranging for the Product to be scheduled in any applicable controlled substance schedule(s) in countries in the Territory. GW agrees, without additional consideration, to give all necessary consents, declarations and documentation as are reasonably required to implement the foregoing and to provide Novartis with all assistance reasonably requested by Novartis (including attending meetings with Regulatory Authorities in any such country) for the purpose of arranging for such scheduling.
(b) Subject to Section 6.1(g), Novartis (or its applicable Affiliate or Sublicensee) will file and hold all Regulatory Approvals for the Products in countries in the Territory in its own name and on its own behalf. Unless otherwise agreed by the Parties, within ten (10) Business Days following the Effective Date, GW will assign to Novartis all Regulatory Filings with any Regulatory Authority in the Territory at the Effective Date relating to any Product and Novartis will reimburse GW all fees paid by GW to Regulatory Authorities in such countries with respect to the submission of such Regulatory Filings. On request by Novartis, GW will deliver notices of such assignment to the applicable Regulatory Authorities. In addition, GW agrees to give all necessary consents, declarations and documentation as are reasonably required to implement the foregoing.
(c) Subject to Sections 4.2 and 6.1(e), Novartis (or its applicable Affiliate or Sublicensee) will be responsible for conducting, at its sole expense, such activities directed towards obtaining and maintaining Regulatory Approvals for Products in the Territory as it determines appropriate in its sole discretion; provided, however, that Novartis agrees to submit Regulatory Filings for Marketing Approvals for a Product in each of the Key Countries. Thereafter, Novartis shall, on a Key Country-by-Key Country basis further prosecute all such Regulatory Filings in the Key Countries in a timely, professional and diligent manner, including by paying all required filing fees promptly and responding to correspondence and requests for further information from Regulatory Authorities in the Key Countries within a reasonable timeframe. Novartis shall share with GW its plans for obtaining Regulatory Approvals in the Key Countries at the first JSC meeting and thereafter shall supply GW with its updated plan from time to time. Novartis shall report its performance against this regulatory plan to the JSC each Calendar Quarter.
(d) Novartis will: (A) determine the regulatory plans and strategies for the Products in the Territory; (B) (either itself or through its Affiliates or Sublicensees and subject to Section 6.1(g)) make and own all Regulatory Filings with respect to the Products in the Territory; and (C) will be responsible for obtaining and maintaining Regulatory Approvals with respect to the Products in the Territory in the name of Novartis or its Affiliates or Sublicensees. Accordingly:
(i) Novartis, shall at its own cost write, assemble, otherwise prepare and file all Regulatory Filings required to obtain Regulatory Approvals for Products in the Territory;
(ii) Novartis shall be the principal contact with all Regulatory Authorities on all matters pertaining to any Product, but shall consult regularly with GW regarding such matters, giving due regard to GW’s views;
(iii) Novartis shall provide to GW copies of all substantive correspondence with Regulatory Authorities in the Territory related to any Product, and, to the extent practicable, shall consult with GW in advance of submitting any material correspondence related to any Product to any such Regulatory Authority;
(iv) GW shall provide to Novartis copies of all substantive correspondence with the EMA related to any Product and, to the extent practicable, shall consult with Novartis in advance of submitting any material correspondence related to any Product to the EMA in circumstances where such correspondence could reasonably be expected to impact on the Commercialization and/or Regulatory Approvals of any Product in the Territory;
(v) Novartis shall provide such notice to GW as is reasonably practicable under the circumstances of upcoming meetings related to any Product with Regulatory Authorities in the Territory. Subject to the consent of the relevant Regulatory Authority, GW shall be entitled to attend any such meetings as an observer, and Novartis may require GW’s attendance at any such meeting it deems to be potentially material; and
(vi) Novartis shall pay all filing and maintenance costs of Regulatory Filings and Regulatory Approvals for the Product in the Territory during the Term.
(e) GW shall, without additional consideration, fully cooperate with and provide assistance to Novartis in connection with filings to any Regulatory Authority relating to the Product(s) in the Territory in order to obtain or maintain Regulatory Approvals (including Pricing and/or Reimbursement Approvals, where applicable), including by (i) providing Novartis with an electronic copy of the registration dossier for the Product in the European Union as well as providing Novartis with an electronic copy of this registration dossier in eCTD format if and when available in eCTD format, and upon request by Novartis, an electronic copy of a draft of the registration dossier for the Product in the US as soon as such draft is made available to GW (if this draft is made available to GW in eCTD format GW will provide it to Novartis in eCID format); (ii) upon request by Novartis, providing Novartis with draft responses to any requests from Regulatory Authorities in the Territory related to the Development or manufacture of Products (including any requests related to the chemistry manufacturing and controls (CMC) section of any Regulatory Filing); and (iii) executing any required documents, providing access to personnel and providing Novartis with copies of all reasonably required documentation. To the extent requested by Novartis, GW shall also grant or cause to be granted to Novartis and its Affiliates or Sublicensees, within thirty (30) days of receipt of a written request from Novartis, cross-reference rights to any relevant drug master files and other filings submitted by GW or its Affiliates with any Regulatory Authority and any Regulatory Approval for Product issued by any Regulatory Authority to GW or its Affiliates.
(f) Subject to Novartis having access to reimbursement data from outside the Territory, data generated by Novartis for reimbursement shall be available for GW and its ex-Territory licensees of the Products to use with respect to the Products outside the Territory.
(g) In the event that (A) it is not possible under applicable Laws for Novartis to file for or hold Regulatory Approvals for the Product in any country in the Territory and/or (B) if requested by Novartis in writing to do so, to the extent permitted by applicable Laws and for the duration determined by Novartis, GW will file and/or hold all Regulatory Approvals for the Products in such country, at Novartis’s cost and expense (provided that all such costs and expenses shall be in accordance with a plan and budget agreed in writing by the Parties prior to GW making any such Regulatory Filing), and:
(i) GW will be responsible for, and will use diligent efforts in, obtaining and maintaining all Regulatory Approvals necessary for the Commercialization of the Products in the country in question;
(ii) GW will provide to Novartis copies of all substantive written communications between GW (or its Affiliates) and any Regulatory Authority in the Territory relating to any Product;
(iii) Novartis shall have the right to review and comment upon any Regulatory Filings and correspondence from GW (or its Affiliates) to any Regulatory Authority in the Territory relating to any Product, and GW shall incorporate or address all such comments unless otherwise agreed between the Parties;
(iv) GW will request and seek to arrange such meetings and consultations with Regulatory Authorities in the Territory which may be requested by Novartis, with respect to any Product;
(v) To the extent permitted by the relevant Regulatory Authorities, Novartis shall have the right to have representatives of Novartis attend and participate in all meetings between GW (or its Affiliates) and any Regulatory Authority in the Territory relating to any Product; it being understood and agreed that to the extent permitted by the relevant Regulatory Authorities, Novartis will lead discussions with any such Regulatory Authority in the Territory. If the applicable Regulatory Authority does not permit Novartis to lead any such discussion, GW will lead the applicable discussions as directed by Novartis; and
(vi) Novartis will reimburse GW any and all costs incurred pursuant to the foregoing and in accordance with the agreed plan and budget as follows. Within thirty (30) days after each Calendar Quarter during which GW has incurred any such costs and expenses, GW will provide to Novartis a detailed accounting of all such costs and expenses, and shall submit an invoice to Novartis substantially in the form of Exhibit C with respect to the amount of such costs and expenses. Unless disputed, Novartis shall pay such amount within sixty (60) days after receipt of such invoice.
(h) Novartis hereby grants, and undertakes to cause its Affiliates and Sublicensees to grant, to GW and its Affiliates cross-reference rights to any Regulatory Filing for Product submitted by Novartis or its Affiliates or Sublicensees to any Regulatory Authority in the Territory and any Marketing Approval for Product issued by any Regulatory Authority in the Territory to Novartis or its Affiliates or Sublicensees. Novartis shall also grant such cross-reference rights to those of GW’s licensees of the Products for countries outside the Territory for which Novartis, its Affiliates and Sublicensees are granted corresponding cross-reference rights.
(i) The Parties will discuss at the JSC the appropriate response to any request received by either Party from a Third Party academic institution to conduct any investigator initiated clinical study of a Product in the Territory.
(j) If any information comes into GW’s Control that requires a change to the CMC section of Regulatory Filings or Regulatory Approvals, inside and outside the Territory, to avoid ‘regulatory drift’ GW will inform Novartis in writing of the required change (including by providing the necessary technical documentation in English) and Novartis will file such documentation with the relevant Regulatory Authorities as soon as practicable.
General Manager Secondary Contact Email Secondary Contact Phone Secondary Contact Fax Secondary Contact Mobile 1 Administration Fee Contact Name Administration Fee Contact Email 1 9 Administration Fee Contact Phone 2 0
Skills Development The Company acknowledges the changing pace of technology in the electrical contracting industry and the need for employees to understand those changes and have the necessary skill requirements to keep the Company at the forefront of the industry. The Parties to this Agreement recognise that in order to increase the efficiency, productivity and competitiveness of the Company, a commitment to training and skill development is required. Accordingly, the parties commit themselves to:
i) Developing a more highly skilled and flexible workforce.
ii) Providing employees with career opportunities through appropriate training to acquire the additional skills as required by the Company. Taking into account; The current and future skill needs of the Company. The size, structure and nature of the Company. The need to develop vocational skills relevant to the Company and the Electrical Contracting Industry. Where, by agreement between the employee and employer, an employee undertakes training providing skills, which are not a company specific requirement, any time spent in the completion of this training shall be unpaid.
Professional Development 9.01 Continuous professional development is a hallmark of professional nursing practice. As a self-regulating profession, nursing recognizes the importance of maintaining a dynamic practice environment which includes ongoing learning, the maintenance of competence, career development, career counselling and succession planning. The parties agree that professional development includes a diverse range of activities, including but not limited to formal academic programs; short-term continuing education activities; certification programs; independent learning committee participation. The parties recognize their joint responsibility in and commitment to active participation in the area of professional development.
Business Development Company Buyer is a business development company as defined in Section 202(a)(22) of the Investment Advisors Act of 1940.
General Management In the discharge of its general duty to manage the successful performance of the Services, Vendor shall:
3.2.1.1. within thirty (30) calendar days of the Effective Date, identify to Citizens the primary and secondary management contacts responsible for the oversight and management of Services for Citizens;
3.2.1.2. ensure Vendor Staff tasked with management and oversight of the Services are available promptly to perform Services during Business Hours;
3.2.1.3. ensure each assigned Adjuster submits a time record directly to Vendor’s manager or point of contact. At any time during this Agreement, Citizens may require copies of time records from Vendor;
3.2.1.4. ensure that no Vendor Staff carries a weapon on their person while performing Services;
3.2.1.5. ensure that no Vendor Staff uses impairing drugs, chemicals, or alcohol while performing Services;
3.2.1.6. ensure that Vendor Staff avoid using their duties and obligations under this Agreement to engage in any conduct that could create either an actual or perceived conflict of interest, such as due to an ongoing business relationship with an entity other than Citizens that would enable Vendor Staff to receive an improper benefit or unfair competitive advantage;
3.2.1.7. ensure that the Services comply with the Best Claims Practices & Estimating Guidelines as applicable to each Service Category and any other policies or processes set forth by Citizens, including but not limited to:
a. monitoring applicable file production on a weekly basis to determine compliance with Citizens’ production requirements; and,
b. providing detailed reports to Citizens related to Vendor performance upon request.
Training and Professional Development 11.1 The Employer will develop and maintain an employee training and development plan and provide such plan to the Union upon request. Staff training is intended to provide an opportunity for classified staff employees for training sponsored by the University Training and Development and the UW Medical Centers Organizational Development and Training. Education/Professional Leave is intended to facilitate employee access to continuing education opportunities. Training and educational/professional leave may be used for the purpose of improving job performance, maintaining and increasing proficiency, preparing staff for greater responsibility, or increasing promotional opportunities within the framework of staff positions available at the University.
11.2 Any release time for training for employees accepted for such classes shall be in accordance with the Executive Order (currently No. 52) governing this matter. In the event that two or more employees request the same training period and supervision must limit the number of persons who may participate at one time due to work requirements, the selection will be made on a mutually agreeable basis within the department.
11.3 The training program is a proper subject for discussion by either departmental or University-wide Joint Union/Management Committees.
11.4 If the Employer requires an employee to receive training, reimbursement will be provided in accordance with the University travel rules. Employee attendance at Employer required training, either during or outside working hours, will be considered time worked and compensated in accordance with the provisions of this Agreement.
11.5 Employee attendance at training not required by the Employer and not covered by Executive Order 52, either on approved leave from or outside of working hours, will be voluntary and not considered time worked.
Job Development Job development/placement is individualized and shall include weekly person-to-person job search assistance, assistance with identifying job leads, interview coaching and support, and maintaining a log of job search activities for the purposes of obtaining competitive integrated employment. By mutual consent of the consumer and the THE ARC XXXXXXX COUNTY, these services may be provided in-person or by Skype, FaceTime, or other online communication tools. Job development/placement may also include arranging job trials/job shadowing for individuals with a DORS Trial Work Experience Plan, assistance with completing applications, assistance with employer follow-up after interviews, use of personal employment networks in job search, and resume update. It would include time spent calling employers, visiting and educating employers and similar activities. Job development/placement shall not be paid for using supported employment funding and shall not include the Discovery process, which is pre-vocational in nature and may be completed prior to job development. Up to 60 hours for job search assistance, authorized in 20-hour increments, may be used for job development. Additional hours of job development may be requested and require written justification by THE ARC XXXXXXX COUNTY and approval of the DORS regional/program director. Job Development Reporting. The Employment Service Progress Form is expected to be submitted to DORS on a monthly basis per consumer. This form is available on the DORS website (xxx.xxxx.xxxxxxxx.xxx).
Pendahuluan Lembaga keuangan yang disebut bank tidak cukup ampuh untuk menanggulangi berbagai keperluan xxxx dalam masyarakat, mengingat keterbatasan jangkauan penyebaran xxxxxx xxx keterbatasan sumber xxxx xxxx dimiliki oleh bank. Hal ini semakin nyata terlihat dari banyaknya bank-bank yang dilikuidasi. Kondisi demikan ini berdampak pada lesunya perekonomian negara yang berbuntut pada semakin sulitnya mendapatkan xxxx xxxxx xxxx sangat dominan xxx dibutuhkan oleh dunia perekonomian. Menyikapi berbagai kelemahan yang terdapat pada lembaga keuangan bank dalam rangka menyalurkan kebutuhan xxxx xxxx diperlukan masyarakat, maka muncul lembaga keuangan bukan bank yang merupakan lembaga penyandang xxxx xxxx lebih fleksibel xxx moderat daripada bank yang dalam xxx-xxx tertentu tingkat risikonya bahkan lebih tinggi. Lembaga inilah yang kemudian dikenal sebagai lembaga pembiayaan yang menawarkan model-model formulasi baru dalam hal penyaluran xxxx terhadap pihak- pihak yang membutuhkannya seperti, leasing (sewa guna usaha), factoring (anjak piutang), modal ventura, perdagangan surat berharga, usaha kartu xxxxxx xxx pembiayaan konsumen yang diatur berdasarkan Keppres Nomor 61 Tahun 1988 tentang Lembaga Pembiayaan. Pengertian Lembaga Pembiayaan keuangan bukan bank dapat dilihat dalam Pasal 1 angka (4) Keppres Nomor 61 Tahun 1988 Tentang Lembaga Pembiayaan, yaitu: Lembaga keuangan bukan bank adalah badan usaha yang melakukan kegiatan dibidang keuangan yang secara langsung atau tidak langsung menghimpun xxxx dengan jalan mengeluarkan surat berharga xxx menyalurkannya kedalam masyarakat guna membiayai investasi perusahaan-perusahaan. Salah satu sistim pembiayaan alternatif yang cukup berperan aktif dalam menunjang dunia usaha akhir-akhir ini yaitu pembiayaan konsumen atau dikenal dengan istilah consumer service. Berdasarkan Xxxxx 0 Angka (6) Keppres Nomor 61 Tahun 1988 tentang Lembaga Pembiayaan, Perusahaan Pembiayaan Konsumen adalah Badan usaha yang melakukan pembiayaan pengadaan barang untuk kebutuhan konsumen dengan sistim pembayaran berkala. Dengan demikian, istilah Lembaga Pembiayaan lebih sempit pengertiannya dibandingkan dengan istilah Lembaga Keuangan, Lembaga Pembiayaan adalah bagian dari Lembaga Keuangan. Dewasa ini, jenis pembiayaan konsumen meskipun masih terbilang muda usianya tetapi sudah cukup populer dalam dunia bisnis di Indonesia, mengingat sifat dari transaksi pembiayaan konsumen tersebut mampu menampung masalah-masalah yang tidak dapat dipecahkan dengan jenis pembiayaan yang biasa di bank-bank. Di samping itu besarnya biaya yang diberikan perkonsumen relatif kecil, mengingat barang yang dibidik untuk dibiayai secara pembiayaan konsumen adalah barang- barang keperluan konsumen yang akan dipakai oleh konsumen untuk keperluan hidupnya. Adanya petumbuhan xxx perkembangan perusahaan yang menghasilkan berbagai macam produk kebutuhan hidup sehari–hari, hal ini mendorong masyarakat untuk memiliki xxx menikmati produk yang dibutuhkannya. Produk xxxx xxxxxx dijadikan dalam menggunakan jasa perusahaan pembiayaan konsumen biasanya adalah barang-barang konsumtif seperti barang elektronik, furniture xxx kendaraan bermotor, disisi lain masyarakat belum mampu membelinya secara tunai. Sejak adanya paket kebijaksanaan 20 Desember 1988 (Pakdes 20/88) mulai diperkenalkan pranata hukum, diantaranya pembiayaan konsumen. Dimana lembaga ini dapat dimanfaatkan oleh masyarakat untuk memenuhi kebutuhan produk yang diharapkan/dibutuhkan. Di samping alasan tersebut ada beberapa xxxxxx xxxx dapat dilihat sebagai berikut :
a. Keterbatasan sumber xxxx formal dengan sistim pembiayaan yang fleksibel xxx Tidak memerlukan penyerahan barang jaminan
b. Koperasi pembiayaan sulit berkembang, hal ini dipengaruhi oleh manajemen koperasi di tangani oleh orang–orang yang tidak profesional atau masih bermental individualis (tidak berorientasi kepada kepentingan bersama) dimana pembiayaan xxx pengawasan lebih menekankan pada keberadaannya bukan pada pemanfaatan modal usaha dimana apabila telah mampu menghimpun xxxx xxxx besar, maka cenderung untuk korupsi dengan pemanfaatan modal untuk kepentingan diri sendiri.
c. Bank tidak melayani pembiayaan konsumen, karena Bank tidak melayani kredit yang bersifat konsumtif xxx Bank menerapkan prinsif jaminan dalam pemberian kredit. Dengan adanya lembaga Pembiayaan Konsumen dapat membantu masyarakat berpenghasilan rendah untuk memiliki prodak barang yang mereka butuhkan xxx seringkali barang tersebut mereka jadikan sebagai alat untuk mencari uang guna mendapatkan tambahan dalam memenuhi kebutuhan hidup sehari-hari. Perjanjian pembiayaan konsumen sebagai terobosan terhadap jual beli secara angsuran. Perjanjian pembiayaan merupakan salah satu cara untuk menjawab persoalan masyarakat dalam mendapatkan barang yang dibutuhkan xxx memberikan jalan keluar apabila pihak supplier menghadapi banyak permintaan atau hasrat masyarakat untuk membeli barang tetapi calon pembeli tersebut tidak mampu untuk membayar harga barang tersebut secara tunai. Dalam memenuhi permohonan suatu barang, pihak supplier melibatkan pihak ke 3 (tiga) yaitu perusahaan pembiayaan sebagai penyadang xxxx. Dalam praktek perjanjian yang melibatkan tiga pihak ini yaitu konsumen, supplier xxx perusahaan pembiayaan konsumen, karena pihak supplier pada dasarnya lebih megutamakan penjualan secara tunai untuk menjaga stabilitas keuangan perusahaannya, sehingga untuk memenuhi permohonan kredit dari pembeli, pihak supplier melibatkan perusahaan pembiayaan yang menyediakan xxxx untuk membeli barang dari supplier secara tunai. Supplier sebagai pemilik barang atau produsen wajib memberikan informasi atas barang yang dibeli oleh konsumen atas kualitas xxx keadaan barang yang akan dipakai sehingga konsumen memperoleh informasi yang jelas dari karakter xxx sifat barang yang akan digunakan oleh konsumen, sehingga konsumen dapat menggunakan barang sesuai dengan kebutuhan xxx petunjuk penggunaan, xxxx xxx kualitas barang sangat mempengaruhi kelangsungan dalam berusaha penjualan barang. Maka perlu adanya suatu jaminan atas barang yang dipakai oleh konsumen, xxx perlunya suatu kepastian penggantian bila terjadi kesalahan produksi. Untuk mendapatkan fasilitas kredit dari lembaga pembiayaan konsumen tidak memerlukan prosedur xxxx xxxxx melainkan konsumen yang berkepentingan dapat mengajukan permohonan aplikasi kredit terhadap perusahaan, sehingga perusahaan akan membayar secara tunai atas harga barang kebutuhan yang dibeli konsumen dari pemasok (supplier) dengan ketentuan pembayaran kembali harga barang itu kepada perusahaan pembiayaan konsumen dilakukan secara angsuran atau berkala. Akan tetapi kegiatan perusahaan pembiayaan konsumen seperti ini bukan berarti tidak mengandung resiko. Resiko akan muncul apabila konsumen tidak melakukan pembayaran angsuran secara berkala sebagai kewajibannya sebagaimana yang telah disepakati dalam perjanjian. Disamping itu ada juga konsumen yang menghilangkan atau menjual barang sebagai objek perjanjian tersebut sehingga keberadaan barang tidak diketahui oleh pihak perusahaan pembiayaan konsumen Perkembangan prilaku masyarakat dalam memenuhi kebutuhan hidupnya berdampak pada perkembangan hukum . Hal ini sesuai dengan teori Xxx Xxxxxxx yang menyatakan bahwa perkembangan hukum terjadi karena perubahan prilaku masyarakat, lebih tepat adalah bahwa jiwa rakyatlah (volksgeit) yang hidup xxx bergerak dalam diri semua individu yang menciptakan hukum (Xxxx Xxxxxxx, 2006: 89). Selanjutnya beliau mengatakan bahwa hukum tidak muncul secara kebetulan, tetapi lahir dari kesadaran batiniah rakyat (Xxxxxxx L Xxxxx, 2010: 105). Teori tersebut membawa dampak lahirnya Undang-Undang No 8 Tahun 1999 tentang perlindungan konsumen. Dalam hal seperti ini apabila terjadi sengketa antara konsumen dengan perusahaan pembiayaan menurut ketentuan Pasal 45 ayat 2 Undang – Undang Nomr 8 Tahun 1999 tentang Perlindungan Konsumen disebutkan bahwa penyelesaian perselisihan konsumen dapat ditempuh melalui pengadilan atau diluar pengadilan berdasarkan pilihan sukarela para pihak yang bersengketa. Xxxx xxxxxx terjadi dalam masyarakat adalah perusahaan lebih suka penyelesaiannya diluar pengadilan atau non litigasi. Dengan tujuan agar citra perusahaan tetap dipandang xxxx xxxx masyarakat, karena prosedur-prosedur penyelesaian diluar pengadilan bisa memberikan jaminan kerahasiaan yang sama besarnya bagi setiap pihak yang terlibat seperti xxxx xxxxxx kali ditentukan dalam konferensi penyelesaian masalah (Rachmadi Usman,2002: 13). Selanjutnya Xxxxxxxx Xxxxx, menyatakan bahwa sebagai usaha yang penuh resiko, sebelum memberikan kredit seyogianya harus melakukan analisis kredit yang seksama, teliti, xxx xxxxxx dengan didasarkan pada yang actual xxx akurat, sehingga tidak akan keliru dalam pengambilan keputusan (Rachmadi Usman, 2001: 255). Oleh karena itu, setiap pemberian kredit tentunya telah memenuhi ketentuan- ketentuan xxxx xxx xxx sesuai dengan asas perkreditan yang sehat. Untuk menentukan apakah suatu kredit dikatakan bermasalah atau macet didasarkan pada kolektibilitas kreditnya. Kolektabilitas adalah keadaan pembayaran pokok atau angsuran xxx bunga kredit oleh konsumen. Pasal 1338 KUHPerdata disebutkan bahwa semua perjanjian yang dibuat secara sah, berlaku sebagai undang-undang bagi mereka yang membuatnya, tidak dapat ditarik kembali tanpa persetujuan kedua belah pihak atau xxxxxx xxxxxx-xxxxxx xxxx cukup menurut Undang- Undang xxx harus dilaksanakan dengan itikad baik (Xxxxx Xxxxx Xxxxxxxx, 2000: 233). Sebenarnya yang dimaksud dalam pasal ini adalah, suatu perjanjian yang dibuat secara sah artinya tidak bertentangan dengan undang-undang mengikat kedua belah pihak. Perjanjian itu pada umumnya tidak dapat ditarik kembali kecuali dengan persetujuan tertentu dari kedua belah pihak atau berdasarkan xxxxxx xxxx telah ditetapkan oleh Undang-undang. Ada keleluasaan dari pihak yang berkepentingan untuk memberlakukan hukum perjanjian yang termuat dalam buku III KUHPerdata tersebut, yang juga sebagai hukum pelengkap ditambah pula dengan asas kebebasan berkontrak tersebut memungkinkan para pihak dalam prakteknya untuk mengadakan perjanjian yang sama sekali tidak terdapat di dalam KUHPerdata maupun KUHD, dengan demikian oleh Undang- undang diperbolehkan untuk membuat perjanjian yang harus dapat berlaku bagi para pihak yang membuatnya. Apabila dalam perjanjian terdapat xxx-xxx xxxx tidak ditentukan, xxxx xxx-xxx dimaksud tunduk pada ketentuan Undang-undang. Berdasarkan ketentuan tersebut jelaslah bahwa perjanjian pembiayaan konsumen (Consumer Finance) tunduk pada ketentuan-ketentuan umum untuk hukum perjanjian yang terdapat dalam buku III KUHPerdata sehingga apabila terjadi perselisihan antara para pihak ketentuan- ketentuan tersebutlah yang dapat ditentukan sebagai pedoman dalam penyelesaian. Dalam prakteknya pelaksanaan perjanjian pembiayaan konsumen tidak terlepas dari berbagai hambatan xxx masalah yang menyertainya, sehingga perusahaan pembiayaan konsumen harus menyiapkan berbagai upaya penyelesaian guna mengatasi masalah yang timbul. Berdasarkan latar belakang di atas, xxxx xxxx menjadi permasalahan adalah Bagaimana penyelesaian sengketa antara para pihak sebagai akibat adanya wanprestasi dalam perjanjian pembiayaan konsumen PT. Adira Dinamika Multi Finance. Tbk ?
